{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:57:09Z","timestamp":1782734229514,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jgo.2023.101537","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T09:15:31Z","timestamp":1686129331000},"page":"101537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dexamethasone-sparing regimens with NEPA (netupitant\/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65\u00a0years) fit for cisplatin: A sub-analysis from a phase 3 study"],"prefix":"10.1016","volume":"14","author":[{"given":"Luigi","family":"Celio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2023.101537_bb0005","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1200\/JCO.2014.55.3065","article-title":"Supportive care considerations for older adults with cancer","volume":"32","author":"Naeim","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2023.101537_bb0010","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jgo.2020.03.001","article-title":"Relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous chemotherapy","volume":"11","author":"Lu-Yao","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2023.101537_bb0015","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jgo.2017.05.003","article-title":"Factors associated with the use of potentially inappropriate medications by older adults with cancer","volume":"8","author":"Moreira Reis","year":"2017","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2023.101537_bb0020","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.1532-5415.2011.03497.x","article-title":"Comparison of prescribing criteria to evaluate the appropriateness of drug treatment in individuals aged 65 and older: a systematic review","volume":"59","author":"Dimitrow","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jgo.2023.101537_bb0025","first-page":"843","article-title":"Impact on daily functioning and indirect\/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population","volume":"19","author":"Haiderali","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jgo.2023.101537_bb0030","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2023.101537_bb0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgo.2016.09.002","article-title":"Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients","volume":"8","author":"Aapro","year":"2017","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2023.101537_bb0040","author":"Multinational Association of Supportive Care in Cancer"},{"key":"10.1016\/j.jgo.2023.101537_bb0045","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2023.101537_bb0050","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jgo.2021.02.018","article-title":"A single-arm feasibility study of gradual dose de-escalation of antiemetic dexamethasone for older patients receiving chemotherapy","volume":"12","author":"Suh","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2023.101537_bb0055","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1634\/theoncologist.2019-0133","article-title":"One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis","volume":"24","author":"Okada","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2023.101537_bb0060","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","article-title":"Placebo-controlled, double-blind phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy","volume":"36","author":"Ito","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2023.101537_bb0065","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1186\/s12885-019-6454-y","article-title":"Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence","volume":"19","author":"Celio","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jgo.2023.101537_bb0070","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1002\/onco.13851","article-title":"Dexamethasone-sparing regimens with oral netupitant and palonosetron for the prevention of emesis caused by high-dose cisplatin: a randomized noninferiority study","volume":"26","author":"Celio","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2023.101537_bb0075","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0959-8049(03)00299-5","article-title":"Functional relevance of antiemetic control: experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant","volume":"39","author":"Martin","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jgo.2023.101537_bb0080","first-page":"522","article-title":"Assessing the impact of chemotherapy-induced nausea and vomiting on patients\u2019 daily lives: a modified version of the functional living index-Emesis (FLIE) with 5-day recall","volume":"11","author":"Martin","year":"2003","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jgo.2023.101537_bb0085","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1186\/s12885-022-10018-3","article-title":"Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant\/palonosetron) in the cisplatin setting: results from a randomized phase 3 study","volume":"22","author":"Celio","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jgo.2023.101537_bb0090","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","article-title":"Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy","volume":"94","author":"Vardy","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jgo.2023.101537_bb0095","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1634\/theoncologist.2015-0211","article-title":"A prospective multicenter study evaluating secondary adrenal suppression after antiemetic dexamethasone therapy in cancer patients receiving chemotherapy: a Korean south west oncology group study","volume":"20","author":"Han","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2023.101537_bb0100","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1634\/theoncologist.2016-0308","article-title":"A prospective observational study on effect of short-term periodic steroid premedication on bone metabolism in gastrointestinal cancer (ESPRESSO-01)","volume":"22","author":"Nakamura","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2023.101537_bb0105","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.4143\/crt.2015.464","article-title":"A pilot study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer patients","volume":"48","author":"Jeong","year":"2016","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.jgo.2023.101537_bb0110","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/annonc\/mdv138","article-title":"Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review","volume":"26","author":"Jordan","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2023.101537_bb0115","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","article-title":"A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy","volume":"25","author":"Aapro","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2023.101537_bb0120","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.2014.58.7550","article-title":"Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer","volume":"33","author":"Nightingale","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2023.101537_bb0125","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1634\/theoncologist.5-3-224","article-title":"Management of cancer in the older person: a practical approach","volume":"5","author":"Balducci","year":"2000","journal-title":"Oncologist"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406823001340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406823001340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:57:40Z","timestamp":1761818260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406823001340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1879406823001340"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2023.101537","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dexamethasone-sparing regimens with NEPA (netupitant\/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65\u00a0years) fit for cisplatin: A sub-analysis from a phase 3 study","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2023.101537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101537"}}